Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artelo Biosciences, Inc. (NASDAQ: ARTL) SEC filings page on Stock Titan provides structured access to the company’s U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on lipid-signaling pathways and the endocannabinoid system, Artelo uses its SEC filings to report on clinical development, capital formation, governance changes, and listing status.
Here you can review Form 10-K annual reports and Form 10-Q quarterly reports (when filed) for detailed discussions of Artelo’s pipeline, including programs such as ART27.13 for cancer anorexia-cachexia syndrome, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, and ART12.11, its CBD-TMP cocrystal composition. These reports typically describe risk factors, research and development priorities, intellectual property, and liquidity and capital resources.
Form 8-K current reports are particularly important for ARTL, as they capture material events such as underwritten public offerings, private placements of convertible notes and warrants, cooperation agreements with shareholders, amendments to bylaws and articles of incorporation, executive appointments, and Nasdaq listing notifications. For example, an 8-K dated November 25, 2025 discloses a Nasdaq delist determination letter related to stockholders’ equity requirements and the company’s intention to appeal.
Investors can also use this page to access registration statements such as Form S-1 and Form S-3, which describe the terms of securities offerings, resale registrations for warrants and convertible notes, and related risk disclosures. Where available, Section 16 filings (Forms 3, 4, and 5) provide insight into insider ownership and transactions involving directors and officers.
Stock Titan’s platform enhances these filings with AI-generated summaries that highlight key terms, financial and capital structure changes, and program-related disclosures, helping users quickly understand how each document relates to Artelo’s clinical pipeline, governance, and Nasdaq listing status.
Artelo Biosciences is registering up to 9,820,294 shares of Common Stock for resale. The shares consist of 81,000 issued shares, up to 3,107,407 shares issuable on Pre-Funded Warrants, up to 6,376,814 shares issuable on Common Warrants and up to 255,073 shares issuable on Placement Agent Warrants.
The Company is not selling any shares here and will not receive proceeds from resale by the Selling Stockholders; however, Artelo may receive up to $21,508,908.56 in gross proceeds if the Warrants and Placement Agent Warrants are exercised for cash. The prospectus discloses Beneficial Ownership Limitation provisions (4.99% or 9.99% election) and cashless-exercise conditions for certain Warrants.
Artelo Biosciences, Inc. is registering 9,820,294 shares of common stock for resale by existing investors under a Form S-1. The shares relate to an March 27, 2026 private placement of 81,000 shares, 3,107,407 pre-funded warrant shares, 6,376,814 common warrant shares and 255,073 placement agent warrant shares.
Artelo will not receive proceeds from stockholder resales but may receive up to $21.5 million in gross proceeds if the warrants are exercised for cash, which it expects to use for working capital, general corporate purposes and repayment of bridge debt. Its stock trades on Nasdaq as “ARTL,” with a $6.61 closing price on April 6, 2026. The prospectus highlights significant dilution and resale overhang risks for existing holders.
Artelo Biosciences has regained compliance with Nasdaq’s continued listing standards. Nasdaq confirmed the company now meets Listing Rule 5550(b)(1), known as the Equity Rule, and Listing Rule 5620(a), the Annual Shareholders Meeting Rule. Nasdaq will monitor Artelo for one year under a mandatory panel monitor.
The company highlights continued progress across its pipeline, including ART27.13, which showed encouraging Phase 2 CAReS interim data in cancer anorexia-cachexia syndrome and is also being studied in glaucoma, and ART26.12, a non-opioid candidate for neuropathic pain. Management believes this positions Artelo to pursue long-term shareholder value.
Artelo Biosciences ownership disclosure: Reporting Persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC may be deemed to beneficially own 81,701 shares of Common Stock, equal to 9.99% of the class, based on 817,127 shares outstanding as of March 30, 2026. The 81,701 figure consists of 81,000 shares held by Intracoastal and 701 shares issuable upon exercise of Intracoastal Warrant 1. The filing states blocker provisions that exclude 5,256 and 173,914 warrant shares from these counts; without those blockers the Reporting Persons may be deemed to own 260,871 shares.
Artelo Biosciences entered into definitive agreements for a $11.0 million private placement of 3,188,407 shares of common stock (or pre-funded warrants) plus warrants to buy up to 6,376,814 additional shares. Investors will pay $3.45 per share (or pre-funded warrant) with accompanying warrants.
The warrants will have an exercise price of $3.20 per share, be exercisable upon issuance, and expire five and one-half years after the resale registration statement becomes effective. Artelo plans to use net proceeds for working capital, general corporate purposes, and repayment of certain bridge debt.
The securities are being sold in a private placement exempt from registration under Section 4(a)(2) and/or Regulation D, with the company agreeing to file a resale registration statement for these securities.
Artelo Biosciences is expanding development of its drug candidate ART27.13 as a potential companion therapy to GLP-1 treatments, focusing on preserving muscle mass during weight loss. The company cites observations of muscle-protective effects in its CAReS cancer anorexia and cachexia trial, where the highest-dose cohort showed average weight gain of about 6% versus roughly 5% weight loss in placebo-treated patients.
The strategy is supported by independent peer-reviewed research describing ART27.13 as a GPCR superagonist with differentiated CB2 pharmacology, a provisional patent filing covering use of cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy, and initiation of a non-clinical study in GLP-1–relevant models. Artelo also notes a planned third-party fully funded clinical study starting in Q2 2026 to evaluate ART27.13 in glaucoma, underscoring its intention to position the once-daily, orally administered CB2 agonist across cancer-related anorexia and cachexia, glaucoma, and broader muscle preservation settings.